Semaglutide vs. Tirzepatide for Weight Loss: A Head-to-Head Comparison for 2026

How They Work: Single vs. Dual Agonist

The fundamental difference lies in their mechanisms of action:

• Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which slows gastric emptying, increases satiety signaling to the brain, and improves insulin sensitivity.
• Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, providing a two-pronged approach to appetite regulation, glucose metabolism, and fat utilization.

This dual-agonist mechanism is what gives tirzepatide a potential edge in clinical trials - it targets metabolic pathways that semaglutide alone does not.

Weight Loss Results: What the Clinical Data Shows

A 2026 narrative review in the Journal of Diabetes compared real-world outcomes with RCT data, finding that real-world semaglutide achievers lost 4.7–10.5 kg at 6–12 months, while the SHAPE study showed semaglutide persisters lost ~14.1% of body weight vs. ~16.5% for tirzepatide persisters. RCT per-protocol estimates were higher: semaglutide ~14.9% and tirzepatide 15mg ~20.9% (Bloomgarden, 2026).

A 2024 network meta-analysis in Biomedicines integrating 25 RCTs with 18,257 patients found that tirzepatide significantly outperformed other treatments, including semaglutide, in both HbA1c reduction and weight loss (Ayesh et al., 2024).

Head-to-Head Comparison

• Mechanism: Semaglutide = GLP-1 agonist | Tirzepatide = GLP-1 + GIP dual agonist
• Avg. weight loss (RCT): Semaglutide ~15% | Tirzepatide ~18–21% of body weight
• Max dose: Semaglutide 2.4 mg weekly | Tirzepatide 15 mg weekly
• Administration: Both weekly subcutaneous injection
• Common side effects: Both - nausea, diarrhea, constipation
• Dose escalation: Semaglutide 16–20 weeks | Tirzepatide 20–28 weeks to max dose
• Monthly cost (without insurance): Semaglutide $350–$600 (compounded, historical) to $1,300+ (brand) | Tirzepatide $400–$700 (compounded, historical) to $1,100+ (brand)

The compounded figures above are historical. Compounded semaglutide and tirzepatide are no longer routinely available in the United States following the end of the FDA shortage designation and the related compounding enforcement discretion in 2025. Our guide to compounded vs brand semaglutide has the full picture.

Side Effects: How Do They Compare?

Both medications share similar gastrointestinal side effects - nausea, vomiting, diarrhea, and constipation - which are most common during the dose-escalation phase and typically diminish over time. Key differences:

• Nausea rates are comparable between the two medications at equivalent dose-escalation speeds.
• Discontinuation rates in real-world data are significant for both: the 2026 Journal of Diabetes review found that 20–50% of patients discontinued within one year, most commonly due to side effects, cost, or access issues.
• Cardiovascular safety: Semaglutide has demonstrated MACE (major adverse cardiovascular event) reductions of 20–46% in real-world studies. Head-to-head cardiovascular outcome trials comparing tirzepatide and semaglutide in non-diabetic populations are still needed.

Cost Considerations in Michigan

Cost is often the deciding factor for patients. In Michigan, the landscape changed significantly in 2026:

• Medicare: CMS introduced a new $50/month GLP-1 access program for Medicare beneficiaries, significantly reducing costs for eligible patients.
• Michigan Medicaid: Conversely, Medicaid restricted GLP-1 coverage for weight loss, cutting an estimated $240 million in spending.
• Private insurance: Coverage varies widely. Many plans cover GLP-1 medications for type 2 diabetes but not for weight management alone.
• Compounded options: No longer a routine pathway. Semaglutide came off the FDA shortage list on 21 February 2025, and FDA enforcement discretion for compounding ended on 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities. On 30 April 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, published in the Federal Register on 1 May 2026, with the comment period extended to 30 July 2026; no final determination is confirmable as of August 2026. See compounded vs brand semaglutide for the full picture.

At Arbour Longevity, we prescribe FDA-approved brand GLP-1 medications and work with patients to find the most cost-effective access pathway, including insurance authorization support and transparent monthly pricing.

Which One Is Right for You?

Tirzepatide may be the better choice if:

• You have a significant amount of weight to lose (BMI 35+)
• You also have type 2 diabetes or significant insulin resistance
• You want the maximum weight-loss potential supported by current data

Semaglutide may be the better choice if:

• You have cardiovascular risk factors (stronger MACE reduction data)
• You prefer a medication with a longer real-world safety track record
• Cost is a primary concern and your insurance coverage favors semaglutide
• You have a moderate amount of weight to lose

Ultimately, the best medication is the one you can tolerate, afford, and persist with at the target dose.

Our Approach at Arbour Longevity

Medical weight loss at Arbour Longevity goes beyond simply prescribing a GLP-1 medication. Gandhi Bhattarai, FNP-BC, PMHNP-BC takes an integrated approach that may include:

• Comprehensive metabolic lab work before starting any medication
• Hormone optimization (BHRT) to address underlying metabolic imbalances
• Peptide therapy (MOTS-c, BPC-157) to support mitochondrial function and gut health
• Body composition monitoring to ensure you're losing fat, not muscle
• Ongoing dose titration and side-effect management

This integrated model is what separates a longevity clinic from a GLP-1 prescription mill.

Frequently Asked Questions

Can I switch from semaglutide to tirzepatide (or vice versa)?

Yes, switching is common when a patient plateaus on one medication or experiences intolerable side effects. Your provider will determine the appropriate starting dose for the new medication based on your current dose and response. We walk through the whole transition - timing, the dose ladder, and what the first two months feel like - in our companion guide, switching from semaglutide to tirzepatide.

Will I regain weight if I stop taking GLP-1 medications?

Studies show that weight regain is common after discontinuation, which is why lifestyle modifications and metabolic optimization are essential components of any medical weight loss program. At Arbour Longevity, we develop long-term strategies - not just prescriptions.

Can I still get compounded semaglutide or tirzepatide?

Not as a routine option. Semaglutide came off the FDA shortage list on 21 February 2025, and the enforcement discretion that had allowed widespread compounding ended on 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities. FDA has since proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List. Arbour Longevity does not routinely supply compounded GLP-1 medications. Our guide to compounded vs brand semaglutide explains where things currently stand.

How soon will I see results?

Most patients notice reduced appetite within the first 1–2 weeks. Measurable weight loss typically begins within the first month, with the most significant results occurring at 3–6 months as you reach the optimal dose.

Find out which GLP-1 medication is right for you. Book a consultation at Arbour Longevity in Ann Arbor. We'll review your labs, medical history, and weight loss goals to recommend the best medication and build a comprehensive plan for lasting results.